These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 2669990)

  • 21. Escalation, group and A + B designs for dose-finding trials.
    Ivanova A
    Stat Med; 2006 Nov; 25(21):3668-78. PubMed ID: 16381057
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Incorporating toxicity considerations into the design of two-stage phase II clinical trials.
    Bryant J; Day R
    Biometrics; 1995 Dec; 51(4):1372-83. PubMed ID: 8589229
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Validity and efficiency of approximation methods for tied survival times in Cox regression.
    Hertz-Picciotto I; Rockhill B
    Biometrics; 1997 Sep; 53(3):1151-6. PubMed ID: 9333345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating survival and association in a semicompeting risks model.
    Lakhal L; Rivest LP; Abdous B
    Biometrics; 2008 Mar; 64(1):180-8. PubMed ID: 17645782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Dose-response relationship: relevance for medical practice].
    Klinkhardt U; Harder S
    Med Klin (Munich); 2000 May; 95(1 Spec No):9-14. PubMed ID: 10851842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Continuous toxicity monitoring in phase II trials in oncology.
    Ivanova A; Qaqish BF; Schell MJ
    Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Score tests for dose effect in the presence of non-responders.
    Luo X; Boos DD; Tamura RN
    Stat Med; 2004 Dec; 23(23):3581-91. PubMed ID: 15534896
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose.
    Contrera JF; Matthews EJ; Kruhlak NL; Benz RD
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):185-206. PubMed ID: 15546675
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A group-sequential design for clinical trials with treatment selection.
    Stallard N; Friede T
    Stat Med; 2008 Dec; 27(29):6209-27. PubMed ID: 18792085
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stratified and randomized play-the-winner rule.
    Liang Y; Carriere KC
    Stat Methods Med Res; 2008 Dec; 17(6):581-93. PubMed ID: 18375460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A sample-size-optimal Bayesian procedure for sequential pharmaceutical trials.
    Cressie N; Biele J
    Biometrics; 1994 Sep; 50(3):700-11. PubMed ID: 7981396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Estimation of a parameter and its exact confidence interval following sequential sample size reestimation trials.
    Cheng Y; Shen Y
    Biometrics; 2004 Dec; 60(4):910-8. PubMed ID: 15606411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using projection for testing goodness-of-fit in regression models for repeated measures.
    Qu RP; Palta M
    Biometrics; 1996 Dec; 52(4):1259-67. PubMed ID: 8962453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Kernel estimates of dose response.
    Staniswalis JG; Cooper V
    Biometrics; 1988 Dec; 44(4):1103-19. PubMed ID: 3233249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Partly conditional survival models for longitudinal data.
    Zheng Y; Heagerty PJ
    Biometrics; 2005 Jun; 61(2):379-91. PubMed ID: 16011684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. On the use of concordant pairs in matched case-control studies.
    Liang KY; Zeger SL
    Biometrics; 1988 Dec; 44(4):1145-56. PubMed ID: 3233251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An approach to categorical data with nonignorable nonresponse.
    Park T
    Biometrics; 1998 Dec; 54(4):1579-90. PubMed ID: 9883554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Optimal response-adaptive designs for normal responses.
    Biswas A; Bhattacharya R
    Biom J; 2009 Feb; 51(1):193-202. PubMed ID: 19197961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designs for phase II trials allowing for a trade-off between response and toxicity.
    Conaway MR; Petroni GR
    Biometrics; 1996 Dec; 52(4):1375-86. PubMed ID: 8962459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.